Stomach-Partitioning Surgery to Help Block Obstruction in Advanced Stomach Cancer
Official title: Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (GO-PART Study, KLASS 16)
Run by Gyeongsang National University Hospital · NCT07749326 · Data updated 2026-11-12
This trial tests whether stomach-partitioning gastrojejunostomy helps people with unresectable, advanced stomach cancer better tolerate food after surgery than the standard approach.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 85 Years |
| Sex | All |
| Enrollment | 144 (estimated) |
| Sponsor | Gyeongsang National University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Changwon, Gyeongsangnam-do) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | July 31, 2028 |
| Study ends | July 31, 2030 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT07749326 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20–85 with histologically confirmed unresectable gastric adenocarcinoma confined to the lower third of the stomach and radiologic or endoscopic evidence of obstructive gastric outlet obstruction, with ECOG 0–2 and adequate ASA 1–III.
✕Probably not a fit
Patients with extensive peritoneal metastasis causing bowel obstruction, tumor extension beyond the lower stomach third, need for emergency surgery, severe malnutrition, or active preoperative chemotherapy may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter randomized study compares a stomach-partitioning gastrojejunostomy (SPGJ) with the conventional gastrojejunostomy (CGJ) in adults with unresectable gastric adenocarcinoma causing malignant gastric outlet obstruction. The aim is to see if SPGJ reduces delayed gastric emptying, speeds recovery, shortens hospital stay, and enables earlier chemotherapy. Outcomes include postoperative gastric emptying, complications, hospital course, and survival. The trial is led by Gyeongsang National University Hospital with collaboration from Medtronic and is conducted at a Changwon site in South Korea.
Why it matters
Potential benefit: If successful, SPGJ could become a new surgical standard that improves recovery and quality of life for patients with advanced gastric cancer and obstruction.
How similar studies have gone: Previous studies in similar surgical approaches have shown potential benefits in recovery, but this specific stomach-partitioning strategy for malignant gastric outlet obstruction is being evaluated anew.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Histologically confirmed gastric adenocarcinoma with Gastric Outlet Obstruction (GOO) that is unresectable for cure (e.g., surrounding tissue invasion, localized peritoneal metastasis, distant metastasis)
* Tumor location confined to the lower one-third (Low body 1/3) of the stomach ③ Age between 20 and 85 years
* ECOG Performance Status ≤ 2 ⑤ ASA score Class I to III ⑥ Endoscopic or radiologic evidence of obstructive GOO
Exclusion Criteria:
* Patients with bowel obstruction due to extensive peritoneal metastasis (P3)
* Tumor extension beyond the lower one-third into the middle one-third of the stomach, making partitioning difficult ③ Patients requiring emergency surgery for perforation or hemorrhage ④ Severe malnutrition (serum albumin \< 2.5} g/L) ⑤ Patients currently undergoing pre-operative chemotherapy
Where it's running
-
Gyeongsang National University Changwon hospital
Changwon, Gyeongsangnam-do, South Korea Recruiting
Study contacts
- Study coordinator: Sang-Ho Jeong, MD, PhD
- Email: shjeong@gnu.ac.kr
- Phone: +82-55-214-3774
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer
This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.
-
TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery
A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.
-
Maintenance therapy in metastatic gastric cancer: a multicenter look from Colombia
This study reviews medical records of adults with metastatic gastric cancer in Colombia to see how patients fare after starting maintenance therapy following initial chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
TEAS timing to aid recovery after stomach cancer surgery
This trial tests whether transcutaneous electrical acupoint stimulation (TEAS) given around surgery helps people recover faster after laparoscopic gastrectomy for gastric cancer.
-
Gastrointestinal Magnet System for Creating a Gastroenterostomy
This study tests the GT Metabolic Magnet System to see if it can safely create a side-to-side gastroenterostomy for adults with gastric outlet obstruction.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.